Dublin, April 07, 2016 -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Drug Delivery in Cancer - Technologies, Markets and Companies" to their offering.
Drug delivery remains a challenge in management of cancer. Approximately 12.5 million new cases of cancer are being diagnosed worldwide each year and considerable research is in progress for drug discovery for cancer. Cancer drug delivery is no longer simply wrapping up cancer drugs in a new formulations for different routes of delivery. The focus is on targeted cancer therapy. The newer approaches to cancer treatment not only supplement the conventional chemotherapy and radiotherapy but also prevent damage to normal tissues and prevent drug resistance.
The market value of drug delivery technologies and the anticancer drugs are difficult to separate. Cancer market estimates from 2015-2025 are given according to organs involved and the types of cancer as well as according to technologies. Distribution of the into major regions is also described.
Profiles of 230 companies involved in developing innovative cancer therapies and methods of delivery are presented along with their 268 collaborations. The bibliography contains over 650 publications that are cited in the report.The report is supplemented with 66 tables and 12 figures.
Key Topics Covered:
Part I: Technologies & Markets
Executive Summary
1. Introduction to cancer therapy
2. Innovative treatments for cancer
3. Drug delivery systems for cancer
4. Delivery of Biological Therapies for Cancer
5. Delivery strategies according to cancer type and location
6. Cancer drug delivery markets
7. References
Part II: Companies
8. Companies involved in cancer drug delivery
For more information visit http://www.researchandmarkets.com/research/7w4tsr/drug_delivery_in
Source: Jain PharmaBiotech
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Drug Delivery, Oncology


Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 



